PMV Pharmaceuticals, Inc.

For the period ended Sep 30, 2025. Filed Nov 12, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 12, 2025

PMVP$1.22-2.4%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)

Condensed Consolidated Statements of Opera tions and Comprehensive Loss

	Three Months Ended September 30,		Nine Months Ended September 30,
	2025	2024	2025	2024
Operating expenses:
Research and development	$18,210	$16,947	$54,050	$44,760
General and administrative	4,312	4,941	12,914	15,520
Total operating expenses	22,522	21,888	66,964	60,280
Loss from operations	(22,522)	(21,888)	(66,964)	(60,280)
Other income (expense):
Interest income, net	1,480	2,615	5,105	8,368
Other (expense) income, net	(23)	121	(44)	103
Total other income	1,457	2,736	5,061	8,471
Loss before provision (benefit) for income taxes	(21,065)	(19,152)	(61,903)	(51,809)
Provision (benefit) for income taxes	(6)	74	(2,198)	(16,100)
Net loss	(21,059)	(19,226)	(59,705)	(35,709)
Unrealized gain (loss) on available for sale investments, net of tax	69	591	(55)	211
Foreign currency translation gain (loss)	1	4	7	(25)
Total other comprehensive income (loss)	70	595	(48)	186
Total comprehensive loss	$(20,989)	$(18,631)	$(59,753)	$(35,523)
Net loss per share -- basic and diluted	$(0.40)	$(0.37)	$(1.14)	$(0.69)
Weighted-average common shares outstanding	52,993,238	51,574,027	52,322,523	51,499,818

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.